Study design and participants
migraine, Headache
MIGRAINE
This was a randomized, double-blind, placebo-controlled, crossover, phase 4 trial performed in five Italian Headache Centers from 30 July 2019 to 5 July 2021.The study included a screening (6 weeks), run-in (4 weeks) and a treatment phase (24 weeks). After run-in, patients were randomized to 12-weeks of subcutaneous erenumab 140 mg or masked placebo, followed by 12-weeks of the other treatment (Fig. Schematic description of study design and study procedures. Eligible patients had to be older than 18 years, have ≥ 4 and < 15 migraine days/month and have failed two or more previous migraine preventives. See supplementary methods for detailed inclusion/exclusion criteria.